Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Novel Antiretroviral Agents

  • 131 Accesses

Abstract

Purpose of Review

Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development.

Recent Findings

Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV.

Summary

New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.

This is a preview of subscription content, log in to check access.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.

    Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV. Lancet. 2018;392(10148):685–97.

  2. 2.

    Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–91.

  3. 3.

    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.

  4. 4.

    Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–9.

  5. 5.

    World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018.

  6. 6.

    Thenin-Houssier S, Valente ST. HIV-1 capsid inhibitors as antiretroviral agents. Curr HIV Res. 2016;14(3):270–82.

  7. 7.

    Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6(12):e1001220.

  8. 8.

    Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13(8):471–83.

  9. 9.

    Carnes SK, Sheehan JH, Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr Opin HIV AIDS. 2018;13(4):359–65.

  10. 10.

    Tse WL, Link JO, Mulato A, Niedziela-Majka A, Rowe W, Somoza JR, Villasenor AG, Yant SR, Zhang JR, Zheng J. Discovery of novel potent HIV capsid inhibitors with long-acting potential. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2017.

  11. 11.

    Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat Med. 2019;25(9):1377–84.

  12. 12.

    Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, et al. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017;72(10):2954–5.

  13. 13.

    Zheng J, Yant SR, Ahmadyar S, Chan TY, Chiu A, Cihlar T, Link JO, Lu B, Mwangi JW, Rowe W, Schroeder SD, Stepan GJ, Wang KW, Subramanian R, Tse WC. GS-6207: a novel, potent and selective first-in-class inhibitor of HIV 1 capsid function displays nonclinical pharmacokinetics supporting long acting potential in humans. IDSA Annual Meeting. San Francisco, California; 2018.

  14. 14.

    Safety, pharmacokinetics, and antiviral activity of GS-6207 administered subcutaneously in HIV-1 infected adults. [Available from: https://ClinicalTrials.gov/show/NCT03739866].

  15. 15.

    Mascolini M. Sharp drops in HIV load after 10 days of capsid inhibitor monotherapy. International AIDS Society. Mexico City, Mexico; 2019.

  16. 16.

    Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, et al. Secondgeneration HIV‐1 maturation inhibitor BMS‐955176: antiviral activity and safety with atazanavir +/- ritonavir. International AIDS Society. Vancouver, Canada; 2015.

  17. 17.

    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′, 3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007;51(10):3574–81.

  18. 18.

    McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther. 2008;13(Suppl 3):A10.

  19. 19.

    Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009;53(5):2185–8.

  20. 20.

    Nowicka-Sans B, Protack T, Lin Z, Li Z, Zhang S, Sun Y, et al. Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and Gag polymorphic coverage. Antimicrob Agents Chemother. 2016;60(7):3956–69.

  21. 21.

    Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, et al. Antiviral activity, safety, and exposure–response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002). Clin Infect Dis. 2017;65(3):442–52.

  22. 22.

    Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, et al. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: week 24 primary analysis from a randomized phase IIb trial. PLoS One. 2018;13(10):e0205368.

  23. 23.

    DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico C, Jeffrey J, Gan K, Felizarta FB, Scribner A, Rampogal M, Benson P, Johns BA. A phase IIa study of novel maturation inhibitor GSK2838232 in HIV patients. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2019.

  24. 24.

    Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, et al. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacol Res Perspect. 2018;6(4):e00408.

  25. 25.

    Matthews RP, Schurmann D, Rudd DJ, Levine V, Fox-Bosetti S, Zhang S, et al. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. Paris: International AIDS Society Conference; 2017.

  26. 26.

    Grobler J, Fillgrove K, Hazuda D, Huang Q, Lai M, Matthews RP, Rudd DJ, Vargo R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington; 2019.

  27. 27.

    Grobler J, Friedman E, Barrett S, Wood S, Androm W, Fillgrove K, Lai M, Gindy M, Iwamoto M, Hazuda D. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 2016.

  28. 28.

    Markowitz M, Gettie A, St Bernard L, Mohri H, Grasperge B, Blanchard J, Sun L, Fillgrove K, Hazuda D, Grobler J. Low dose MK-8591 protects rhesus macaques against rectal SHIV infection. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 2018.

  29. 29.

    Safety and pharmacokinetics of oral islatravir (MK-8591) once monthly in participants at low risk of human immunodeficiency virus 1 (HIV-1) infection (MK-8591-016). [Available from: https://clinicaltrials.gov/ct2/show/NCT04003103].

  30. 30.

    Matthews R. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. International AIDS Society Conference. Mexico City, Mexico; 2019.

  31. 31.

    • Barrett SE, Teller RS, Forster SP, Li L, Mackey MA, Skomski D, et al. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother. 2018;62(10):e01058–18 This study evaluated the pharmacokinetics of islatravir-eluting implants in rhesus macaques.

  32. 32.

    Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992;149(5):1779–87.

  33. 33.

    Moore J, Sattentau Q, Klasse P, Burkly L. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol. 1992;66(8):4784–93.

  34. 34.

    Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology. 2002;172(3):191–203.

  35. 35.

    Pace CS, Fordyce MW, Franco D, Kao C-Y, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013;62(1):1–9.

  36. 36.

    Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011;85(8):3872–80.

  37. 37.

    Khanlou H DJ, Fessel J, Schrader S, Towner W, Weinheimer S, Lewis S. Durable efficacy and continued safety of ibalizumab in treatment-experienced patients. IDSA Annual Meeting. Boston, Massachusetts; 2011.

  38. 38.

    • Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645–54 This study demonstrated that ibalizumab had significant antiviral activity in adults with MDR HIV-1, prompting FDA approval.

  39. 39.

    Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One. 2012;7(3):e32599.

  40. 40.

    Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010;6(5):e1000880.

  41. 41.

    Ding X, Zhang X, Chong H, et al. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition. J Virol. 2017;91(18). https://doi.org/10.1128/JVI.00831-17

  42. 42.

    Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:8.

  43. 43.

    Xie D. Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomized, controlled, phase 3, non-inferiority TALENT study. HIV Glasgow. Glasgow, UK; 2016.

  44. 44.

    Albuvirtide. U.S. Department of Health and Human Services. [Available from: https://aidsinfo.nih.gov/drugs/586/albuvirtide/0/patient].

  45. 45.

    Albuvirtide and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects (ABL). [Available from: https://clinicaltrials.gov/ct2/show/NCT03719664?cond=albuvirtide&draw=2&rank=2].

  46. 46.

    Lataillade M, Lalezari J, Aberg J, Molina JM, Kozal M, Cahn P, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study). International AIDS Society Conference. Mexico City, Mexico; 2019.

  47. 47.

    ViiV Compassionate Use. 2019. [Available from: https://viiv-cu-portal.idea-point.com/Documents/Status%20of%20drugs%20in%20the%20ViiV%20Compassionate%20Use%20Program.pdf].

  48. 48.

    Al-Salama ZT. Elsulfavirine: first global approval. Drugs. 2017;77(16):1811–6.

  49. 49.

    Ratanasuwan W, Peerawong W, Koryakova A, Berzins B, Bichko V, Murphy R. Pharmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients. International AIDS Society Conference. Melbourne, Australia; 2014.

  50. 50.

    Phase Ib study of safety, tolerability and pharmacokinetics of elpida once weekly in healthy volunteers. [Available from: https://clinicaltrials.gov/ct2/show/NCT03730311].

  51. 51.

    Murphy R, Kravchenko A, Orlova-Morozova E, Nagimova F, Kozirev O, Shimonava T, Deulina M, Vostokova N, Zozulya O, Bichko V. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2017.

Download references

Acknowledgements

Mary Catherine Cambou was supported by the UCLA Postdoctoral Fellowship Training Program in Global HIV Prevention Research (Currier and Gorbach, PIs); T32MH080634. Dr. Landovitz was supported by the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH grant P30MH58107.

Author information

Correspondence to Mary C. Cambou.

Ethics declarations

Conflict of Interest

Raphael J. Landovitz has received research grants from, and served as a consultant to Gilead Sciences; and served as a consultant to Merck and Co, Inc. Dr. Landovitz received honoraria and travel support from Gilead Sciences, Merck, Inc, and Roche.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on HIV Pathogenesis and Treatment

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cambou, M.C., Landovitz, R.J. Novel Antiretroviral Agents. Curr HIV/AIDS Rep (2020). https://doi.org/10.1007/s11904-020-00486-2

Download citation

Keywords

  • HIV/AIDS
  • New antiretrovirals
  • Capsid inhibitors
  • Maturation inhibitors
  • Nucleoside reverse transcriptase translocation inhibitors
  • Anti-CD4 antibodies